MX2017013080A - Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). - Google Patents

Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).

Info

Publication number
MX2017013080A
MX2017013080A MX2017013080A MX2017013080A MX2017013080A MX 2017013080 A MX2017013080 A MX 2017013080A MX 2017013080 A MX2017013080 A MX 2017013080A MX 2017013080 A MX2017013080 A MX 2017013080A MX 2017013080 A MX2017013080 A MX 2017013080A
Authority
MX
Mexico
Prior art keywords
chain polypeptide
interleucine
receiver
antibodies against
directed antibodies
Prior art date
Application number
MX2017013080A
Other languages
English (en)
Spanish (es)
Inventor
J King David
John Mcknight Andrew
Bowers Peter
Londei Marco
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of MX2017013080A publication Critical patent/MX2017013080A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2017013080A 2015-04-15 2016-04-15 Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). MX2017013080A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562147824P 2015-04-15 2015-04-15
PCT/US2016/027676 WO2016168542A1 (en) 2015-04-15 2016-04-15 Antibodies directed against interleukin 36 receptor (il-36r)

Publications (1)

Publication Number Publication Date
MX2017013080A true MX2017013080A (es) 2018-02-09

Family

ID=57126337

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017013080A MX2017013080A (es) 2015-04-15 2016-04-15 Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
MX2023001791A MX2023001791A (es) 2015-04-15 2017-10-11 Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023001791A MX2023001791A (es) 2015-04-15 2017-10-11 Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).

Country Status (14)

Country Link
US (3) US10526410B2 (OSRAM)
EP (2) EP4176900A1 (OSRAM)
JP (4) JP6913026B2 (OSRAM)
KR (1) KR102666920B1 (OSRAM)
CN (2) CN115925932A (OSRAM)
AU (1) AU2016248208B2 (OSRAM)
CA (1) CA2982555A1 (OSRAM)
DK (1) DK3283110T3 (OSRAM)
ES (1) ES2914243T3 (OSRAM)
MX (2) MX2017013080A (OSRAM)
PL (1) PL3283110T3 (OSRAM)
RU (1) RU2745898C2 (OSRAM)
SG (1) SG11201708061TA (OSRAM)
WO (1) WO2016168542A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031948B1 (ru) 2011-11-16 2019-03-29 Бёрингер Ингельхайм Интернациональ Гмбх Антитело к il-36r или его антигенсвязывающий фрагмент, выделенный полинуклеотид, клетка-хозяин и способ получения этого антитела или его фрагмента, содержащая их фармацевтическая композиция и применение антитела или его фрагмента и композиции
MX2017013080A (es) * 2015-04-15 2018-02-09 Anaptysbio Inc Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
WO2018183173A1 (en) * 2017-03-27 2018-10-04 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
EP3400962A1 (en) 2017-05-09 2018-11-14 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Inhibitors of il-38 for use in treating and/or preventing cancer in a subject
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CA3090421A1 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
IL277215B2 (en) * 2018-03-14 2025-10-01 Boehringer Ingelheim Int Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis
CN112513091B (zh) * 2018-07-16 2024-08-27 瑞泽恩制药公司 抗il36r抗体
WO2020018511A1 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
CN110818796B (zh) * 2018-08-09 2022-11-08 东莞市朋志生物科技有限公司 一种抗人ca153蛋白的重组抗体
AR123405A1 (es) * 2018-12-21 2022-11-30 23Andme Inc Anticuerpos anti-il-36 y métodos de uso de estos
TW202037604A (zh) * 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
CA3132917A1 (en) * 2019-03-08 2020-09-17 Boehringer Ingelheim International Gmbh Anti-il-36r antibody formulations
AU2020325315A1 (en) 2019-08-07 2022-03-24 Aqualung Therapeutics Corp. Anti-NAMPT antibodies and uses thereof
WO2021112196A1 (ja) * 2019-12-05 2021-06-10 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
KR20230038774A (ko) 2020-07-17 2023-03-21 베링거 인겔하임 인터내셔날 게엠베하 호중성 피부병의 치료를 위한 항-il-36r 항체
AU2021319103A1 (en) * 2020-07-30 2023-02-09 Anaptysbio, Inc. Anti-interleukin 36 receptor (IL-36r) therapy for ichthyosis
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
JP7662804B2 (ja) * 2021-03-04 2025-04-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 汎発性膿疱性乾癬を処置する方法
US20220290239A1 (en) 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
CN117615788A (zh) * 2021-05-12 2024-02-27 安奈普泰斯生物有限公司 抗体组合物
WO2023285362A1 (en) 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗ｉｌ－３６ｒ抗體
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
DE69128037T2 (de) 1990-11-13 1998-05-07 Immunex Corp., Seattle, Wash. Bifunktionelle wählbare fusionsgene
CA2163427A1 (en) 1993-05-21 1994-12-08 Stephen D. Lupton Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AU2001233212A1 (en) 2000-02-02 2001-08-14 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
EP2074139B1 (en) 2006-09-08 2013-10-23 Amgen, Inc Il-1 family variants
EP2126087A4 (en) 2007-02-20 2010-10-27 Anaptysbio Inc METHODS FOR PRODUCING PHARMACOTHEQUES, AND USES THEREOF
EP2337799A2 (en) 2008-08-28 2011-06-29 Wyeth LLC Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
EA031948B1 (ru) * 2011-11-16 2019-03-29 Бёрингер Ингельхайм Интернациональ Гмбх Антитело к il-36r или его антигенсвязывающий фрагмент, выделенный полинуклеотид, клетка-хозяин и способ получения этого антитела или его фрагмента, содержащая их фармацевтическая композиция и применение антитела или его фрагмента и композиции
US9475872B2 (en) * 2011-12-28 2016-10-25 Immunoqure Ag Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F
JP6162319B2 (ja) 2013-03-12 2017-07-12 デシミューン セラピューティクス，インコーポレイテッド ヒト化抗ｎ２抗体
MX2017013080A (es) * 2015-04-15 2018-02-09 Anaptysbio Inc Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
WO2018183173A1 (en) 2017-03-27 2018-10-04 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
CA3090421A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
IL277215B2 (en) 2018-03-14 2025-10-01 Boehringer Ingelheim Int Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis
CN112513091B (zh) 2018-07-16 2024-08-27 瑞泽恩制药公司 抗il36r抗体
AR123405A1 (es) 2018-12-21 2022-11-30 23Andme Inc Anticuerpos anti-il-36 y métodos de uso de estos
TW202037604A (zh) 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
CA3132917A1 (en) 2019-03-08 2020-09-17 Boehringer Ingelheim International Gmbh Anti-il-36r antibody formulations
US20220233710A1 (en) 2019-05-20 2022-07-28 Nantong Yichen Biopharma. Co. Ltd. Bispecific molecule and preparation and use thereof

Also Published As

Publication number Publication date
US11130814B2 (en) 2021-09-28
ES2914243T3 (es) 2022-06-08
EP3283110A1 (en) 2018-02-21
HK1250941A1 (en) 2019-01-18
RU2745898C2 (ru) 2021-04-02
CN107847590B (zh) 2022-07-26
DK3283110T3 (da) 2022-05-23
US20200087408A1 (en) 2020-03-19
SG11201708061TA (en) 2017-10-30
EP3283110B1 (en) 2022-04-20
RU2017139481A (ru) 2019-05-15
JP2021118710A (ja) 2021-08-12
JP2018512157A (ja) 2018-05-17
US20180094065A1 (en) 2018-04-05
EP4176900A1 (en) 2023-05-10
JP2023040236A (ja) 2023-03-22
US20210388095A1 (en) 2021-12-16
US10526410B2 (en) 2020-01-07
CA2982555A1 (en) 2016-10-20
AU2016248208B2 (en) 2022-03-24
BR112017022086A2 (pt) 2018-07-03
JP2025163120A (ja) 2025-10-28
JP6913026B2 (ja) 2021-08-04
CN107847590A (zh) 2018-03-27
US12391761B2 (en) 2025-08-19
JP7721585B2 (ja) 2025-08-12
KR102666920B1 (ko) 2024-05-20
CN115925932A (zh) 2023-04-07
JP7212098B2 (ja) 2023-01-24
KR20180002687A (ko) 2018-01-08
EP3283110A4 (en) 2019-02-27
AU2016248208A1 (en) 2017-11-09
HK1252009A1 (zh) 2019-05-10
NZ736535A (en) 2024-08-30
MX2023001791A (es) 2023-03-10
RU2017139481A3 (OSRAM) 2019-09-19
WO2016168542A1 (en) 2016-10-20
PL3283110T3 (pl) 2022-06-27

Similar Documents

Publication Publication Date Title
MX2017013080A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
MX2022000112A (es) Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3).
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
MX2019003886A (es) Receptores de antigenos quimericos para el tratamiento del cancer.
SA519401370B1 (ar) الأجسام المضادة وحيدة النسيلة المبتكرة لبروتين الموت المبرمج (pd-1)
ZA201708265B (en) Tigit-binding agents and uses thereof
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
MX2020001272A (es) Anticuerpos dirigidos contra interleucina-33 (il-33).
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
EA201891992A1 (ru) Химерные рецепторы и способы их применения
MX372817B (es) Anticuerpos dirigidos contra la proteína muerte programada-1 (pd-1).
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
BR112013002831A2 (pt) anticorpos direcionados contra a il-17
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
WO2015116569A3 (en) Antibodies directed against discoidin domain receptor family, member 1 (ddr1)
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
EA201992747A1 (ru) Антитела к fam19a5 и их применение
EA202092895A1 (ru) Агонистические антитела против cd226